Quetiapine extended-release versus immediate-release formulation: A positron emission tomography study

David C. Mamo, Hiroyuki Uchida, Irina Vitcu, Penny Barsoum, Alain Gendron, Jeffrey Goldstein, Shitij Kapur

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Objective: The pharmacokinetic and pharmacodynamic profile of the immediate-release (IR) formulation of quetiapine is characterized by a rapid peak in plasma level and striatal dopamine D2 receptor occupancy, followed by a rapid decrease to baseline levels, necessitating the use of twice-daily dosing. An extended-release (XR) formulation of quetiapine is currently being developed to achieve similar efficacy using a once-daily dosing regimen. We compared the central D2 receptor binding between the IR and XR formulations. Method: In this open-label, crossover positron emission tomography study using [11C]-raclopride, we compared the central D2 receptor binding potential at expected peak and trough plasma levels using equivalent daily doses of the IR and XR formulations (300, 600, and 800 mg/day) in 12 subjects. Data were collected from April 2002 to May 2003. Results: The mean plasma level of quetiapine at trough was significantly lower than that at peak for all dose groups of both formulations except for IR 300 and 800 mg (all p values < .05), while the mean plasma level did not differ significantly between formulations at trough and peak. The mean occupancy at peak was significantly higher than that at trough for all dose groups other than IR 800 mg/day (all p values < .05) and did not differ significantly between formulations at trough and peak. Conclusion: Once-daily dosing of the XR formulation gives peak and trough plasma levels and central D2 receptor occupancy comparable to twice-daily dosing of the IR formulation. These data should be considered while determining equivalent doses, as well as switching strategies.

Original languageEnglish
Pages (from-to)81-86
Number of pages6
JournalJournal of Clinical Psychiatry
Volume69
Issue number1
Publication statusPublished - 2008 Jan
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Raclopride
Corpus Striatum
Dopamine D2 Receptors
Pharmacokinetics
Quetiapine Fumarate

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Mamo, D. C., Uchida, H., Vitcu, I., Barsoum, P., Gendron, A., Goldstein, J., & Kapur, S. (2008). Quetiapine extended-release versus immediate-release formulation: A positron emission tomography study. Journal of Clinical Psychiatry, 69(1), 81-86.

Quetiapine extended-release versus immediate-release formulation : A positron emission tomography study. / Mamo, David C.; Uchida, Hiroyuki; Vitcu, Irina; Barsoum, Penny; Gendron, Alain; Goldstein, Jeffrey; Kapur, Shitij.

In: Journal of Clinical Psychiatry, Vol. 69, No. 1, 01.2008, p. 81-86.

Research output: Contribution to journalArticle

Mamo, DC, Uchida, H, Vitcu, I, Barsoum, P, Gendron, A, Goldstein, J & Kapur, S 2008, 'Quetiapine extended-release versus immediate-release formulation: A positron emission tomography study', Journal of Clinical Psychiatry, vol. 69, no. 1, pp. 81-86.
Mamo, David C. ; Uchida, Hiroyuki ; Vitcu, Irina ; Barsoum, Penny ; Gendron, Alain ; Goldstein, Jeffrey ; Kapur, Shitij. / Quetiapine extended-release versus immediate-release formulation : A positron emission tomography study. In: Journal of Clinical Psychiatry. 2008 ; Vol. 69, No. 1. pp. 81-86.
@article{45e45db784eb41b9878283dbff85b9f3,
title = "Quetiapine extended-release versus immediate-release formulation: A positron emission tomography study",
abstract = "Objective: The pharmacokinetic and pharmacodynamic profile of the immediate-release (IR) formulation of quetiapine is characterized by a rapid peak in plasma level and striatal dopamine D2 receptor occupancy, followed by a rapid decrease to baseline levels, necessitating the use of twice-daily dosing. An extended-release (XR) formulation of quetiapine is currently being developed to achieve similar efficacy using a once-daily dosing regimen. We compared the central D2 receptor binding between the IR and XR formulations. Method: In this open-label, crossover positron emission tomography study using [11C]-raclopride, we compared the central D2 receptor binding potential at expected peak and trough plasma levels using equivalent daily doses of the IR and XR formulations (300, 600, and 800 mg/day) in 12 subjects. Data were collected from April 2002 to May 2003. Results: The mean plasma level of quetiapine at trough was significantly lower than that at peak for all dose groups of both formulations except for IR 300 and 800 mg (all p values < .05), while the mean plasma level did not differ significantly between formulations at trough and peak. The mean occupancy at peak was significantly higher than that at trough for all dose groups other than IR 800 mg/day (all p values < .05) and did not differ significantly between formulations at trough and peak. Conclusion: Once-daily dosing of the XR formulation gives peak and trough plasma levels and central D2 receptor occupancy comparable to twice-daily dosing of the IR formulation. These data should be considered while determining equivalent doses, as well as switching strategies.",
author = "Mamo, {David C.} and Hiroyuki Uchida and Irina Vitcu and Penny Barsoum and Alain Gendron and Jeffrey Goldstein and Shitij Kapur",
year = "2008",
month = "1",
language = "English",
volume = "69",
pages = "81--86",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "1",

}

TY - JOUR

T1 - Quetiapine extended-release versus immediate-release formulation

T2 - A positron emission tomography study

AU - Mamo, David C.

AU - Uchida, Hiroyuki

AU - Vitcu, Irina

AU - Barsoum, Penny

AU - Gendron, Alain

AU - Goldstein, Jeffrey

AU - Kapur, Shitij

PY - 2008/1

Y1 - 2008/1

N2 - Objective: The pharmacokinetic and pharmacodynamic profile of the immediate-release (IR) formulation of quetiapine is characterized by a rapid peak in plasma level and striatal dopamine D2 receptor occupancy, followed by a rapid decrease to baseline levels, necessitating the use of twice-daily dosing. An extended-release (XR) formulation of quetiapine is currently being developed to achieve similar efficacy using a once-daily dosing regimen. We compared the central D2 receptor binding between the IR and XR formulations. Method: In this open-label, crossover positron emission tomography study using [11C]-raclopride, we compared the central D2 receptor binding potential at expected peak and trough plasma levels using equivalent daily doses of the IR and XR formulations (300, 600, and 800 mg/day) in 12 subjects. Data were collected from April 2002 to May 2003. Results: The mean plasma level of quetiapine at trough was significantly lower than that at peak for all dose groups of both formulations except for IR 300 and 800 mg (all p values < .05), while the mean plasma level did not differ significantly between formulations at trough and peak. The mean occupancy at peak was significantly higher than that at trough for all dose groups other than IR 800 mg/day (all p values < .05) and did not differ significantly between formulations at trough and peak. Conclusion: Once-daily dosing of the XR formulation gives peak and trough plasma levels and central D2 receptor occupancy comparable to twice-daily dosing of the IR formulation. These data should be considered while determining equivalent doses, as well as switching strategies.

AB - Objective: The pharmacokinetic and pharmacodynamic profile of the immediate-release (IR) formulation of quetiapine is characterized by a rapid peak in plasma level and striatal dopamine D2 receptor occupancy, followed by a rapid decrease to baseline levels, necessitating the use of twice-daily dosing. An extended-release (XR) formulation of quetiapine is currently being developed to achieve similar efficacy using a once-daily dosing regimen. We compared the central D2 receptor binding between the IR and XR formulations. Method: In this open-label, crossover positron emission tomography study using [11C]-raclopride, we compared the central D2 receptor binding potential at expected peak and trough plasma levels using equivalent daily doses of the IR and XR formulations (300, 600, and 800 mg/day) in 12 subjects. Data were collected from April 2002 to May 2003. Results: The mean plasma level of quetiapine at trough was significantly lower than that at peak for all dose groups of both formulations except for IR 300 and 800 mg (all p values < .05), while the mean plasma level did not differ significantly between formulations at trough and peak. The mean occupancy at peak was significantly higher than that at trough for all dose groups other than IR 800 mg/day (all p values < .05) and did not differ significantly between formulations at trough and peak. Conclusion: Once-daily dosing of the XR formulation gives peak and trough plasma levels and central D2 receptor occupancy comparable to twice-daily dosing of the IR formulation. These data should be considered while determining equivalent doses, as well as switching strategies.

UR - http://www.scopus.com/inward/record.url?scp=39549115004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39549115004&partnerID=8YFLogxK

M3 - Article

C2 - 18312041

AN - SCOPUS:39549115004

VL - 69

SP - 81

EP - 86

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 1

ER -